Ignite Creation Date:
2025-12-24 @ 11:57 PM
Ignite Modification Date:
2025-12-25 @ 9:54 PM
Study NCT ID:
NCT00910858
Status:
COMPLETED
Last Update Posted:
2013-09-30
First Post:
2009-05-28
Is NOT Gene Therapy:
False
Has Adverse Events:
True
Brief Title:
A Pharmacokinetic And Pharmacodynamic Study Of Oral Lenalidomide (Revlimid) In Subjects With Low- Or Intermediate-1-Risk Myelodysplastic Syndromes
Sponsor:
Celgene Corporation
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2005-01
Start Date Type:
None
Primary Completion Date:
2006-04
Primary Completion Date Type:
ACTUAL
Completion Date:
2009-05
Completion Date Type:
ACTUAL
First Submit Date:
2009-05-28
First Submit QC Date:
None
Study First Post Date:
2009-06-01
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2013-07-31
Results First Submit QC Date:
None
Results First Post Date:
2013-09-30
Results First Post Date Type:
ESTIMATED
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2013-07-31
Last Update Post Date:
2013-09-30
Last Update Post Date Type:
ESTIMATED